Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tap

Showing results (141-150 of 235) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.
Clinical Orthopaedics and Related Research|August 24, 2022
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVENJohn H Healey, William D Tap, Heather L Gelhorn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 29, 2023
Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy ResponseIsrael S Kasago, Walid K Chatila, Cecilia M Lezcano, et al.
The Oncologist|December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsJames H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
JACC. Cardiovascular Imaging|July 6, 2023
Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac MassesAngel T Chan, Tania Ruiz Maya, Christine Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical OutcomeEvan Rosenbaum, Kenneth Seier, Chaitanya Bandlamudi, et al.
Acta Orthopaedica|May 12, 2021
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trialMichiel Van De Sande, William D Tap, Heather L Gelhorn, et al.
Journal for Immunotherapy of Cancer|September 29, 2024
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analysesNathan D Seligson, James L Chen, Austin C Goodrich, et al.
Pageof 24

Showing results (141-150 of 235) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.
Clinical Orthopaedics and Related Research|August 24, 2022
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVENJohn H Healey, William D Tap, Heather L Gelhorn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 29, 2023
Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy ResponseIsrael S Kasago, Walid K Chatila, Cecilia M Lezcano, et al.
The Oncologist|December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsJames H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
JACC. Cardiovascular Imaging|July 6, 2023
Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac MassesAngel T Chan, Tania Ruiz Maya, Christine Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical OutcomeEvan Rosenbaum, Kenneth Seier, Chaitanya Bandlamudi, et al.
Acta Orthopaedica|May 12, 2021
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trialMichiel Van De Sande, William D Tap, Heather L Gelhorn, et al.
Journal for Immunotherapy of Cancer|September 29, 2024
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analysesNathan D Seligson, James L Chen, Austin C Goodrich, et al.
Pageof 24